Author

G. Boross

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Evolutionary Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:chromatin & epigenetic regulation· 2 Organism:human· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Approach:comparative / phylogenetic analysis· 1 Research Focus:development & morphogenesis· 1

Frequent Co-Authors

D. A. Petrov· 3 shared L. Andrejka· 3 shared M. M. Winslow· 3 shared J. D. Hebert· 2 shared M. Yousefi· 2 shared B. Papp· 1 shared C. A. Kunder· 1 shared C. I. Colon· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. A. Petrov

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Combinatorial in vivo genome editing identifies widespread epistasis during lung tumorigenesis

J. D. Hebert, Y. J. Tang, L. Andrejka, S. S. Lopez, D. A. Petrov, G. Boross, M. M. Winslow

The paper uses in vivo genome editing to study genetic interactions in lung cancer, finding widespread negative epistasis among tumor suppressor genes.

bioRxiv · Mar 7, 2024 · PreprintCancer Biology

Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma

M. Yousefi, L. Andrejka, M. M. Winslow, D. A. Petrov, G. Boross

This study characterizes the fitness landscapes of tumor suppressor genes in oncogene-negative lung adenocarcinoma, finding that multiple mutations can drive tumor growth with minimal constraints on mutational order.

bioRxiv · Jan 30, 2023Cancer Biology

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities

M. Yousefi, G. Boross, C. Weiss, C. W. Murray, J. D. Hebert, H. Cai, E. L. Ashkin, S. Karmakar, L. Andrejka, L. Chen, M. Wang, M. K. Tsai, W.-Y. Lin, C. Li, P. Yakhchalian, , M. M. Winslow

This study identifies RAS/PI3K pathway activation as a common driver in oncogene-negative lung adenocarcinomas and shows these tumors are vulnerable to targeted therapy.

bioRxiv · Oct 20, 2021Cancer Biology

Pathogen diversity drives the evolution of promiscuous peptide binding of human MHC-II alleles

M. Manczinger, G. Boross, L. Kemeny, V. Muller, T. Lenz, B. Papp, C. Pal

This study shows that pathogen diversity drives the evolution of promiscuous peptide binding in human MHC-II alleles, explaining their global distribution and immune function.

bioRxiv · Jul 17, 2018Evolutionary Biology